Also known as Synagis
Palivizumab (brand name Synagis which is manufactured by MedImmune) is a monoclonal antibody produced by recombinant DNA technology. It is used in the prevention of respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease.Source: Wikipedia
Patients are most commonly prescribed palivizumab to treat congenital heart defect, interstitial lung disease, rabies, and blastomycosis.